Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

Rahway: Merck, known as MSD outside of the United States and Canada, and Moderna, Inc., announced the initiation of INTerpath ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, Merck MRK, Pfizer PFE, AbbVie ABBV and Novartis NVS — announcing their results ...

The drugmaker emphasized plans to move further away from singular reliance on Keytruda while reporting solid sales growth in ...

Daniel Quirk, an immunology and neuroscience executive at Bristol Myers Squibb, will be Biogen’s next chief medical officer. Meanwhile, Robin Kramer will replace retiring CFO Michael McDonnell.

On Monday, Merck & Co Inc (NYSE:MRK) and Moderna, Inc. (NASDAQ:MRNA) announced the initiation of INTerpath-009, a pivotal ...

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.

a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti ...